Analogs of thalidomide as potential angiogenesis inhibitors

Details Analogs of thalidomide as potential angiogenesis inhibitors Analogs of thalidomide as potential angiogenesis inhibitors

2008-01-22

2008-01-22

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

10469359

ABSTRACT:
A number of thalidomide metabolites having superior anti-angiogenic properties have now been isolated and identified. In addition, thalidomide analogs that mimic the effects of the isolated and identified active thalidomide metabolites, and variations of such thalidomide analogs, have been developed. Such thalidomide analog compounds show enhanced potency in the inhibition of undesirable angiogenesis without the undesirable effects of administration of thalidomide.

REFERENCES:
patent: 2830991 (1958-04-01), Keller et al.
patent: 3314953 (1967-04-01), Vazakas et al.
patent: 3320270 (1967-05-01), Grogan et al.
patent: 3560495 (1971-02-01), Frankus et al.
patent: 3794641 (1974-02-01), Görög et al.
patent: 4092147 (1978-05-01), Ashkar et al.
patent: 4291048 (1981-09-01), Gold et al.
patent: 5434170 (1995-07-01), Andrulis, Jr.
patent: 5593990 (1997-01-01), D'Amato
patent: 5605684 (1997-02-01), Piacquadio
patent: 5629327 (1997-05-01), D'Amato
patent: 5712291 (1998-01-01), D'Amato
patent: 5783605 (1998-07-01), Kuo et al.
patent: 5789434 (1998-08-01), Kluender et al.
patent: 5840724 (1998-11-01), Fenton et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6080742 (2000-06-01), Germann et al.
patent: 6096768 (2000-08-01), Ashton et al.
patent: 6110941 (2000-08-01), Zimmer et al.
patent: 6124322 (2000-09-01), Bjoerkman et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6306879 (2001-10-01), Germann et al.
patent: 6417197 (2002-07-01), Schneider et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: 6762195 (2004-07-01), Muller et al.
patent: 2001/0041716 (2001-11-01), Laing et al.
patent: 2002/0022627 (2002-02-01), Dannenberg
patent: 2002/0161023 (2002-10-01), D'Amato
patent: 2003/0013739 (2003-01-01), Masferrer
patent: 2003/0181428 (2003-09-01), Green et al.
patent: 2005/0004087 (2005-01-01), D'Amato et al.
patent: 2104776 (1992-08-01), None
patent: 2251060 (1997-03-01), None
patent: 2228385 (1998-01-01), None
patent: 2248838 (1998-10-01), None
patent: 2302886 (2000-03-01), None
patent: 33 32 633 (1985-04-01), None
patent: 0 856 513 (1996-08-01), None
patent: 0 908 176 (1999-04-01), None
patent: 1 336 602 (2003-08-01), None
patent: 962857 (1964-07-01), None
patent: 1075420 (1967-07-01), None
patent: 1049283 (1996-11-01), None
patent: WO 92/18496 (1992-10-01), None
patent: WO 94/20085 (1994-09-01), None
patent: WO 95/17154 (1995-06-01), None
patent: WO 96/20705 (1996-07-01), None
patent: WO 96/20926 (1996-07-01), None
patent: WO 97/012652 (1997-04-01), None
patent: WO 97/23457 (1997-07-01), None
patent: WO 97/37988 (1997-10-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/19649 (1998-05-01), None
patent: WO 98/025895 (1998-06-01), None
patent: WO 99/013873 (1999-03-01), None
patent: WO 99/58096 (1999-11-01), None
patent: WO 99/059960 (1999-11-01), None
patent: WO 99/59960 (1999-11-01), None
patent: WO 01/74362 (2001-10-01), None
patent: WO 02/064083 (2002-08-01), None
patent: WO 02/068414 (2002-09-01), None
patent: WO 03/014315 (2003-02-01), None
patent: WO 03/097052 (2003-11-01), None
patent: WO 2004/085422 (2004-10-01), None
patent: WO 2005/016325 (2005-02-01), None
patent: WO 2005/016326 (2005-02-01), None
Shimazawa et al. “Antiagngiogenic activity . . .” CA 130:320368 (1999).
Ching et al. “Interaction of thalidomide . . .” Ca 129:285590 (1998).
Understanding angiogenesis “About angiogenesis” Angiogenesis foundation from web (2005).
Ni et al. “Experimental study on activity of . . .” CA 138:100441 (2002).
Isner et al. “Therapeutic angiogenesis” Frontiers inBioscience, v. 3, p. 49-69 (1998).
Marks et al. “Effect of putative . . .” Biol. Pharm bull, V. 25 p. 597-604 (2002).
Pagani et al. , FRPSX,Farmaco Ed. Sci.25: 203-225 (1970).
Pratt and Young, JACSATJ. Amer. Chem.Soc. 40:1420 (1918).
Teubert et al., ARPMASArch. Pharm.(Weinheim Ger.) 331:7-12 (1998).
De et al., “Possible Antineoplastic Agents: III—Synthesis of 6-Alkyl-2-[4′methoxyphthalimido] and 6-Alkyl-3-[3′-4′-dimethoxyphenyl] glutarimides,”J. Indian Chem. Soc.LIII:1122-1125, 1976.
De et al., “Possible Antineoplastic Agents: Part IV—Synthesis & Antineoplastic Potency of N-Substituted α-(4,5-Dimethoxyphthalimido)glutarimides & N-Substituted β-(4-Bromophenyl)glutarimides,”Indian J. of Chem.16B:510-512, 1978.
Hess et al., “Synthesis and immunological activity of water-soluble thalidomide prodrugs,”Bioorganic and Medicinal Chem.9(5):1279-1291, 2001.
Lentzsch et al., “S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice,”Cancer Research62:2300-2305, 2002.
Lepper et al., “Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors,”J. Medicinal Chem.47(9):2219-2227, 2004.
NG et al., “Antiangiogenic Activity of N-substituted and Tetrafluorinated Thalidomide Analogues,”Cancer Research63(12):3189-3194, 2003.
Zhang, “Preparation of water-soluble thalidomide derivative,” Database CA Online, Chemical Abstracts Service, Database accession No. 2004:817880, 2004, abstract.
Bauer et al.,Biochemical Pharmacology55:1827-1834, 1998.
D'Amato et al.,Proc. Nat'l. Acad. Sci. USA91:4082-4085, 1995.
Gütschow et al.,Bioorganic&Medicinal Chemistry9:1059-1065, 2001.
Neumann et al.,The Journal of Biological Chemistry269(34)21561-21567, 1994.
Teubert et al.,Arch. Pharm. Pharm. Med Chem.331:7-12, 1998.
Bartlett et al., “Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patents with metastatic malignant melanoma and other advanced cancers,”British Journal of Cancer90:955-961, 2004.
Bray et al., “Improved Procedures for the Preparation of (+)—(1R, 2S, 4R)-4-Amino-2-Hydroxy-1-Hydroxymethl Cyclopentante,”Tetrahedron Letters36(25):4483-4486, 1995.
Cava et al., “Thionation Reactions of Lawesson's Reagents,”Tetrahedron41(22)5061-5087, 1985.
Corral et al., “Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α,”The Journal of Immunology163:380-386, 1999.
Davies et al., “Thalidomide (Thal) and Immunomodulatory Derivatives (IMiDs) Augment Natural Killer (NK) Cell Cytotoxicity in Multiple Myeloma (MM),” American Society of Hematology, 42ndAnnual Meeting, San Francisco, CA, Dec. 1-5, 2000 (Abstract No. 3617).
Davis et al., “Thalidomide (Thal) and Immunomodulatory Derivatives (IMiDs) Augment Natural Killer (NK) Cell Cytotoxicity in Multiple Myeloma (MM),” VIIIth International Myeloma Workshop, Banff, Canada, May 4-8, 2001 (Abstract No. P222).
Davies et al., “Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma,”Blood98(1):210-216, 2001.
Dalgleish et al., “Thalidomide Analogues CC-5013 and CC-4047 Induce T cell Activation and IL-12 Production in Patients with Both Solid Tumours and Relapsed and Refractory Multiple Myeloma,”British Journal of Cancer88(Suppl. 1)S25-S54 (Abstract P14), 2003.
De et al., “Possible Antineoplastic Agents: III Synthesis of 6-Alkyl-2-U4'Methoxyphalimido and 6-Alkyl-3-U3'-4'-Dimethoxyphenyl Glutarimides,”J. Indian Chem. Soc.53:1122-1125, 1976.
Deckers et al., “Effect on Angiogenic and Antiangiogenic Compounds on the Outgrowth of Capillary Structures from Fetal Mouse Bone Explants,”Laboratory Investigation81(1):5-15, 2001.
Dibbs et al., “Thalidomide and Thalidomide Analogs Suppress TNFα Secretion by Myocytes,”Circulation98(17(Suppl), Abstract No. 1284):I247, 1998.
Dredge et al., 

Affiliated with

Also associated with

Rating

Analogs of thalidomide as potential angiogenesis inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Analogs of thalidomide as potential angiogenesis inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analogs of thalidomide as potential angiogenesis inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3951002